Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 11/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20377702 | 1.00 | PTGFR (0.51) | PTGFRPTGER3ABCC4ABCB11THRB | |
| SCHEMBL1047121 | 1.00 | PTGFR (0.51) | PTGFRPTGER3ABCC4ABCB11THRB | |
| SCHEMBL1047123 | 1.00 | PTGFR (0.51) | PTGFRPTGER3ABCC4ABCB11THRB | |
| SCHEMBL1047136 | 0.93 | PTGFR (0.51) | PTGFRPTGER3ABCC4ABCB11THRB | |
| SCHEMBL1047135 | 0.93 | PTGFR (0.51) | PTGFRPTGER3ABCC4ABCB11THRB | |
| SCHEMBL20377694 | 0.93 | PTGFR (0.51) | PTGFRPTGER3ABCC4ABCB11THRB | |
| SCHEMBL462705 | 0.93 | PTGFR (0.51) | PTGFRPTGER3ABCC4ABCB11THRB | |
| SCHEMBL1459658 | 0.93 | PTGFR (0.51) | PTGFRPTGER3ABCC4ABCB11THRB | |
| SCHEMBL1047119 | 0.91 | PTGFR (0.62) | PTGFRPTGER3ABCC4ABCB11THRB | |
| SCHEMBL20514923 | 0.91 | PTGFR (0.62) | PTGFRPTGER3ABCC4ABCB11THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011032159-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | META COMESTICS, LLC (US) | 2011-03-17 | — | — | WO | claimed |
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | LUBIT BEVERLY W | 2011-01-06 | — | — | US | claimed |
| US-20100074857-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | LIPKIN PAMELA | 2010-03-25 | — | — | US | claimed |
| US-10408838-B2 | Non-invasive biomarker to identify subject at risk of preterm delivery | NYU WINTHROP HOSPITAL (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3382391-A1 | NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECTS AT RISK OF PRETERM DELIVERY | NYU Winthrop Hospital (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-2912458-B1 | NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECTS AT RISK OF PRETERM DELIVERY | NYU WINTHROP HOSPITAL (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180003713-A1 | NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECT AT RISK OF PRETERM DELIVERY | WINTHROP-UNIVERSITY HOSPITAL | 2018-01-04 | — | — | US | disclosed |
| US-9797903-B2 | Non-invasive biomarker to identify subject at risk of preterm delivery | WINTHROP-UNIVERSITY HOSPITAL (US) | 2017-10-24 | — | — | US | disclosed |
| US-20150285800-A1 | NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECT AT RISK OF PRETERM DELIVERY | NYU WINTHROP HOSPITAL | 2015-10-08 | — | — | US | disclosed |
| EP-2912458-A1 | NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECTS AT RISK OF PRETERM DELIVERY | Winthrop-University Hospital (US) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014066568-A1 | NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECTS AT RISK OF PRETERM DELIVERY | WINTHROP-UNIVERSITY HOSPITAL (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20110318308-A1 | LIPOCALIN-TYPE PROSTAGLANDIN D2 SYNTHASE AS A BIOMARKER FOR LUNG CANCER PROGRESSION AND PROGNOSIS | WINTHROP-UNIVERSITY HOSPITAL (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011163554-A2 | LIPOCALIN-TYPE PROSTAGLANDIN D2 SYNTHASE AS A BIOMARKER FOR LUNG CANCER PROGRESSION AND PROGNOSIS | WINTHROP-UNIVERSITY HOSPITAL (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011032159-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | META COMESTICS, LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | LUBIT BEVERLY W | 2011-01-06 | — | — | US | disclosed |
| US-20100074857-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | LIPKIN PAMELA | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | PGF, PTGS1, PTGS2 | PTGFR 5/4885PTGER3 75/4885ABCC4 2628/4885 |
| US-20100074857-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | PTGER1, PGF, PTGER2 | PTGFR 6/4885PTGER3 9/4885ABCC4 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.